Vorinostat

Evidence Level: L5

Predicted Indications: 1

Vorinostat

Pharmacist Assessment Report

Vorinostat: Primary cutaneous B-cell lymphoma

One-Sentence Summary

Vorinostat is an oral histone deacetylase (HDAC) inhibitor, originally used to treat primary cutaneous T-cell lymphoma. The TxGNN model predicts it may be effective for primary cutaneous B-cell lymphoma. Support for this is weak: 4 early-phase clinical trials that are not specific to this disease, and 1 preclinical publication.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Primary cutaneous B-cell lymphoma
TxGNN Prediction Score	0.9921
Evidence Level	L5 (preclinical and mechanistic data only; no disease-specific clinical studies)
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from the source database. Vorinostat is nonetheless a known HDAC inhibitor. Blocking HDAC enzymes increases acetylation of histones and other proteins, which can switch on cell-death pathways and slow the growth of cancer cells.

Both the original and the predicted indications are lymphomas that arise in the skin, so a shared biology is plausible. Preclinical work in mantle cell lymphoma, an aggressive B-cell cancer, shows vorinostat can trigger apoptosis by acetylating pro-apoptotic BH3-only gene promoters. This suggests the mechanism may extend to B-cell lymphomas in general.

However, none of this evidence is specific to primary cutaneous B-cell lymphoma. The prediction is therefore a hypothesis, not an established finding.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00045006	Phase 1	Completed	Not reported	Oral vorinostat (SAHA) in advanced solid tumours and haematological malignancies. Safety and pharmacokinetic data, not specific to cutaneous B-cell lymphoma.
NCT01789255	Phase 2	Completed	12	Pilot of vorinostat with tacrolimus and methotrexate to prevent graft-versus-host disease after stem cell transplant. Different indication.
NCT01567709	Phase 1	Completed	34	Alisertib (Aurora A inhibitor) plus vorinostat in relapsed Hodgkin, B-cell non-Hodgkin and peripheral T-cell lymphoma. Combination design, indirect relevance.
NCT00499811	Phase 1	Completed	15	Dose and pharmacokinetics of vorinostat in solid tumours and lymphoma with liver dysfunction. Safety and pharmacokinetics only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21652541	2011	Preclinical	Clin Cancer Res	Vorinostat induced apoptosis in mantle cell lymphoma through acetylation of pro-apoptotic BH3-only gene promoters.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 11138F	Zolinza	Capsule 100 mg (oral)	Indication text not available in the data compiled for this report

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted (epigenetic) therapy: HDAC inhibitor
Emetogenicity Classification	Please refer to the Product Information (PI)
Monitoring Items	Full blood count (including platelets), serum glucose, electrolytes (potassium, calcium, phosphate), renal and liver function, and ECG (QT interval), consistent with the associated conditions listed below
Handling Protection	Follow local cytotoxic and hazardous drug handling procedures. Please refer to the PI.

Safety Considerations

The following information comes from the TxGNN model (deep learning). The scores may reflect similarities the model learned between related diseases, not biological evidence. It is not taken from approved label text.

Conditions linked to contraindication or caution in the knowledge graph: long QT syndrome (including familial), liver disease, gallbladder disease, thrombocytopenia, anaemia (including macrocytic), hyperglycaemia, diabetes mellitus, diabetic ketoacidosis, potassium deficiency, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disorders, pulmonary embolism, and diarrhoeal disease.
Drug Interactions: 61 interactions were identified. The ones listed are all rated Moderate, and most are with glucose-lowering agents. These include metformin, pioglitazone, sulfonylureas (glimepiride, glipizide, glyburide), SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), GLP-1 agonists (semaglutide, dulaglutide, exenatide), DPP-4 inhibitors (alogliptin, linagliptin), acarbose and insulins. Blood glucose should be monitored closely if vorinostat is used alongside these drugs.

Please refer to the TGA-approved Product Information (PI) for official warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high, but there are no disease-specific clinical studies. The only supporting material is early-phase trials in other cancers and one preclinical paper in a different B-cell lymphoma. The mechanistic argument is plausible but unproven for primary cutaneous B-cell lymphoma.

For context, other predicted indications for vorinostat have much stronger support. Sézary syndrome, a leukaemic variant of cutaneous T-cell lymphoma, is effectively a near-label use. It is backed by the pivotal Phase 2b trial (NCT00091559) and the Phase 3 MAVORIC trial (NCT01728805), in which vorinostat was the comparator. If the aim is to prioritise candidates, that indication is a more evidence-ready starting point.

To proceed, the following is needed:

Disease-specific preclinical data (for example, cell-line or patient-sample studies) in primary cutaneous B-cell lymphoma
Case series or a small exploratory trial in cutaneous B-cell lymphoma
Detailed mechanism of action data
The approved indication wording and the safety sections (warnings and contraindications) from the TGA Product Information for ARTG 11138F
A monitoring plan covering platelets, glucose, electrolytes and QT interval
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.